Market Place
Sourcing Support
Aura Biosciences Reports Q4, Full-Year 2025 Financial Results
30 Mar 2026 //
GLOBENEWSWIRE
Aura Biosciences To Participate In Upcoming Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Aura Biosciences Joins 8th Evercore Healthcare Conference
24 Nov 2025 //
GLOBENEWSWIRE
Aura Biosciences Unveils Q3 2025 Financials And Business Updates
13 Nov 2025 //
GLOBENEWSWIRE
Aura Bio to Attend H.C. Wainwright Global Investment Conference
03 Sep 2025 //
GLOBENEWSWIRE
Aura Biosciences Q2 2025 Financial Results and Highlights
13 Aug 2025 //
GLOBENEWSWIRE
Aura Biosciences Plans Public Offering of Stock and Warrants
15 May 2025 //
GLOBENEWSWIRE
Aura Bio Prices Public Offering of Common Stock & Warrants
15 May 2025 //
GLOBENEWSWIRE
Aura Biosciences Reports Q1 2025 Financial Results and Highlights
15 May 2025 //
GLOBENEWSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
01 May 2025 //
GLOBENEWSWIRE
Aura Biosciences Appoints Teresa Bitetti to Board
02 Apr 2025 //
GLOBENEWSWIRE
Bel-sar Phase 1 Trial Data in NMIBC Presented at EAU Congress
24 Mar 2025 //
GLOBENEWSWIRE
Aura Biosciences Reports Q4 and Full Year 2024 Financial Results
24 Mar 2025 //
GLOBENEWSWIRE
Aura To Present Ph1 Bladder Cancer Data At EAU 2025
03 Mar 2025 //
GLOBENEWSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
25 Feb 2025 //
GLOBENEWSWIRE
Aura Bio to Participate in Evercore ISI HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
Aura Biosciences Reports Q3 2024 Financial Results & Business
12 Nov 2024 //
GLOBENEWSWIRE
With ph. 1 data, Aura has an eye on early-stage bladder cancer
18 Oct 2024 //
FIERCE BIOTECH
Single Low Dose Bel-sar Shows Responses In Bladder Cancer Trial
17 Oct 2024 //
GLOBENEWSWIRE
Aura Reports Positive Phase 2 Results For Bel-sar In Choroidal Melanoma
12 Sep 2024 //
GLOBENEWSWIRE
Aura Biosciences to Present NMIBC Data at Urologic Oncology Event Oct 17
03 Sep 2024 //
GLOBENEWSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Aura Presents Phase 2 Data on Bel-sar for Choroidal Melanoma at Retina Society
26 Aug 2024 //
GLOBENEWSWIRE
Aura Biosciences Presents Phase 2 Data On Bel-Sar For Choroidal Melanoma
26 Aug 2024 //
GLOBENEWSWIRE
Aura Biosciences Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Aura Oncology Webinar Announced: Pioneering Ocular Care Standard
23 May 2024 //
GLOBENEWSWIRE
Aura Biosciences Q1 2024 Financials And Business Highlights
09 May 2024 //
GLOBENEWSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
26 Feb 2024 //
BUSINESSWIRE
Aura Announces First Patient Dosed in Phase 3 Trial Evaluating Bel-sar
07 Dec 2023 //
BUSINESSWIRE
Aura Biosciences Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
08 Nov 2023 //
BUSINESSWIRE
Aura Biosciences Receives FDA Agreement SPA for CoMpass Phase 3 Trial of Bel-sar
06 Nov 2023 //
BUSINESSWIRE
Aura Biosciences Announces Pricing of Public Offering of Common Stock
06 Nov 2023 //
BUSINESSWIRE
Aura to Present Phase 2 Data Evaluating Suprachoroidal Administration of Bel-sar
31 Oct 2023 //
BUSINESSWIRE
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
02 Oct 2023 //
BUSINESSWIRE
Aura Biosciences Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
24 May 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
12 May 2023 //
BUSINESSWIRE
Aura Biosciences Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Aura Biosciences Announces Positive PII Safety Data of Belzupacap Sarotalocan
16 Feb 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
09 Feb 2023 //
BUSINESSWIRE
Aura Biosciences Announces Proposed Public Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Announces Pricing of Public Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Reports 3Q 2022 Financial Results & Provides Clinical Develop
10 Nov 2022 //
BUSINESSWIRE
Aura Announces Global Pha3 Trial Designwith Suprachoroidal Route Administration
10 Nov 2022 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
03 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Announces Interim Phase 2 Data Evaluating AU-011
03 Oct 2022 //
BUSINESSWIRE
Aura details second administration route of its ocular oncology drug from PIII
03 Oct 2022 //
ENDPTS
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in Japan
27 Sep 2022 //
KOREABIOMED
Aura to Present Phase 2 Data Evaluating Suprachoroidal Administration of AU-011
27 Sep 2022 //
BUSINESSWIRE
Aura Bio to Present PII Safety Data Evaluating Suprachoroidal
07 Sep 2022 //
BUSINESSWIRE
Aura to Present Belzupacap Sarotalocan Data from Studies at EURETINA Congress
01 Sep 2022 //
BUSINESSWIRE
Aura Biosciences Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
02 Aug 2022 //
BUSINESSWIRE
Aura Biosciences Receives FDA FTD for Belzupacap Sarotalocan (AU-011)
30 Jun 2022 //
BUSINESSWIRE
Aura Bio Reports Topline Data from Retrospective Study of Belzupacap Sarotalocan
22 Jun 2022 //
BUSINESSWIRE
